Semaglutide NEW

Hybio Pharmaceutical Co., Ltd., established in April 2003, is a national high-tech enterprise specializing in the research, production, and sales of peptide pharmaceuticals. The company was listed on the Shenzhen Stock Exchange in 2011 (stock code: 300199) and it is distinguished as the first peptide enterprise listed in China. With subsidiaries in Pingshan, Wuhan, Hong Kong, Gansu Chengji, and Dali, Han Yu Pharmaceuticals operates in the fields of pharmaceuticals and medical devices. Our main products include peptide raw materials, custom peptides, cosmetic peptides, peptide formulations, solid dosage forms, medical devices, and peptide skincare products. We have achieved significant regulatory milestones, obtaining GMP inspection certifications from various international authorities including NMPA (CFDA) of China, the US FDA, the EU's AEMPS, Brazil's ANVISA, and South Korea's MFDS.